Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

6550--Oncology Testing at Dallas VA Facility

Active
36C25721Q1142Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, plans to award a firm-fixed price contract to Genomic Health, Inc. for oncology testing services specifically involving the Oncotype DX Breast and Prostate tests. These tests, which carry CPT codes 81519 and PLA 0047U respectively, will be used to support physicians in diagnosing and treating veteran patients with breast and prostate cancers. Genomic Health, Inc. holds exclusive patents and FDA approval for the Oncotype DX Breast test—a globally recognized standard of care that helps predict chemotherapy benefits and has demonstrated significant patient outcome improvements through extensive international clinical studies. The contract, which will function as a standing order allowing tests to be requested as needed throughout the performance period, is a sole source procurement justified under statutory authority permitting non-competitive awards. The Oncotype DX Breast Cancer Assay is uniquely provided by Genomic Health, Inc., with patents protecting their technology through at least 2028. The agency is open to receiving capability statements or proposals from other sources to ensure no comparable alternatives exist, but absent any affirmative responses, the award will proceed with Genomic Health. This contract is intended to facilitate earlier and more effective oncology treatment for veterans, leveraging a highly specialized and patented diagnostic testing platform.

General Info

Firm-fixed price contract with Genomic Health for exclusive Oncotype DX oncology testing services.

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

TX

Set-Aside

NONE

Documents

1

36C25721Q1142 - Oncology Testing at Dallas VA Facility

DOCX, Low priority3 pages · special-notice
Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

Posted

special-notice

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → 257-NETWORK Contract Office 17 (36C257)
Contacts1 person available
OfficeSan Antonio, TX, 78240, USA
Office AddressSan Antonio, TX, 78240, USA
Contacts
Isela Loveless - Contracting Officer

Full Description

Show more
Special Notice Notice of Intent to Award a Sole Source Procurement The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract/order to Genomic Health, Inc. for Oncology testing: ITEM # DESCRIPTION CPT Code # EST QUANTITY NEEDED 1 Oncotype DX Breast 81519 48 2 Oncotype DX Prostate PLA 0047U 48 The requested items will be used for oncology testing of veteran patients by physicians orders. Genomic Health Inc provides the only FDA approved Oncotype DX-Breast test proven to predict chemotherapy benefit. The Oncotype DX test is included in all major cancer guidelines worldwide and is now considered as standard of care for women with early-stage breast cancer with unprecedented prospective patient outcomes in more than 50,000 patients from four large, independently run, international studies. This specific testing is needed for Veterans to start treatment earlier for better outcomes. The Oncotype DX Breast Cancer Assay for Ductal Carcinoma in Situ (DCK) and Ivasive Breast Cancer is offered exclusively by Genomic Health Inc. The Genomic Health Inc patent portfolio related to the Oncotype DX assay includes, but is not limited to, the following U.S. Patent Numbers: 7,081,340; 7,858,304; 7,838,224; 8,071,286; 8,329,398; 7,767,391; 7,569,345; 8,034,567; 8,206,919; 8,741,605; 7,939,261; 7,526,387; 7,871,769; 7,930,104 and 8,868,352. The patents are in full force and effect with the latest patent and Oncotype DX Genomic Prostate Score Assay anticipated to expire in 2028. The proposed order will be considered a standing order; where, the tests will be ordered throughout each period of performance, on an as-needed basis. This notice is not to be considered a request for quotations or proposals. A contract will not be awarded based on an offer received in response to this notice; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 7 calendar days from the publication of this notice, a contract/order will be issued to Genomic Health Inc. without any further notice. The proposed contract actions are for reference lab testing, which the government intends to negotiate with only one source. The anticipated statutory authorities permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 8.4. The proposed sole source procurement will be made by a pricing agreement with Genomic Health Inc.

Similar Contracts

Same NAICS industry code

NAICS: 325413
New
Federal
Cost Per Reportable Result Purchase of Immunohistochemistry Reagents for Laboratory Tests.
Solicitation # 36C26027Q0058
The Department of Veterans Affairs, through Network Contracting Office 20, is seeking a comprehensive histology staining workflow system for the Puget Sound Health Care System in Seattle, Washington. The required system must include two immunohistochemistry and two in-situ hybridization immunostainers, two special stainers, and an integrated specimen tracking system to ensure patient safety, maintain a chain of custody, and monitor productivity. The workflow components must be fully automated, communicate with one another, and maintain compatibility with Data Innovations middleware as well as VISTA, Cerner, and any future electronic health record systems acquired by the VA. The contract follows a Cost Per Reportable Result pricing model and spans a base year from February 1, 2027, to January 31, 2028, with four subsequent one-year option periods extending through January 31, 2032. Technical requirements specify that the immunostainers must perform 100% of tests listed in the provided specifications and support simultaneous IHC, ISH, and Direct Immunofluorescence staining. Equipment must support Code 39 and Code 128 barcodes, include a safe hazardous waste removal system, and be provided with an uninterruptible power supply capable of supporting a 15-minute controlled shutdown. The contractor is responsible for the delivery, installation, and removal of equipment at no additional charge and must guarantee a minimum equipment uptime of 98%. Performance and method validation must adhere to CLSI guidelines and College of American Pathologists standards. Additionally, the contractor must comply with strict federal and VA information security directives, including those regarding data confidentiality and media sanitization. Emergency supply orders must be fulfilled within 24 hours of a verbal request, providing enough consumables for one week of normal operation.
260-NETWORK Contract Office 20 (36C260)

POSTED

2 days ago

DEADLINE

in 23 days
View Details
NAICS: 325413
New
Federal
6550--HEMOCHRON SIGNATURE ELITE REAGENTS AND SUPPLIES
Solicitation # 36C26227Q0046
The Department of Veterans Affairs, Network Contracting Office 22, is conducting a sources sought notice for the procurement of FDA approved reagents, supplies, consumables, and quality control materials for Werfen Hemochron Signature Elite instruments. This requirement supports the Pathology and Laboratory Medicine Service at the Southern Arizona VA Health Care System in Tucson, Arizona. The contract structure includes a base year from January 1, 2027, to December 31, 2028, followed by four subsequent option years extending through December 31, 2032. The selected contractor must provide 24/7 technical and product support at no additional cost and ensure all items are fully compatible with existing instrumentation without requiring workflow changes or retraining. Key operational requirements include strict adherence to manufacturer specifications for packaging and temperature control during transport. All supplied materials must maintain a minimum shelf life of 90 days, and shipments must clearly list lot numbers and expiration dates. Standard orders are required to be delivered within four working days, while emergency deliveries for defective or temperature-compromised items must be completed within 24 hours of a verbal order. This procurement is conducted as a brand name or equal acquisition under FAR 52.211-6. Interested respondents must provide their business size status, SAM.gov identifiers, and evidence of compliance with the Buy American Act and the Non-Manufacturer Rule.
262-NETWORK Contract Office 22 (36C262)

POSTED

3 days ago

DEADLINE

in 12 days
View Details

More opportunities from Department Of Veterans Affairs → 257-NETWORK Contract Office 17 (36C257)

Same awarding agency

NAICS: 811310
New
Federal
NTX - Preventive and Corrective Maintenance for Ice
Solicitation # 36C25727Q0009
Solicitation 36C25727Q0009 is a competitive best value procurement issued by the Department of Veterans Affairs, Network Contracting Office 17, for preventive and corrective maintenance of ice machines across the VA North Texas Health Care System. This is a Service-Disabled Veteran-Owned Small Business (SDVOSB) set-aside under NAICS 811310. The contract consists of a base period from November 9, 2026, to November 8, 2027, with four additional option years. The scope of work requires the contractor to provide all labor, materials, and supervision for quarterly preventive maintenance, including cleaning, descaling, and sanitation, as well as corrective repairs to ensure equipment remains safe and operational in accordance with manufacturer specifications, OSHA, CDC, and Joint Commission standards. The contractor must adhere to strict performance standards, including a 4-hour emergency response time for units affecting patient care, a 24-hour priority response, and a 72-hour routine response. Key deliverables include service reports submitted within three business days of visits, quarterly summary reports, and an annual replacement recommendation report. Performance is monitored by the Contracting Officer's Representative (COR) through a Quality Assurance Surveillance Plan focusing on fleet uptime, documentation accuracy, and sanitation. Award decisions will be based on a comparative analysis of technical capability and past performance. Offers are due by October 27, 2026, and must include a signed SF 1449, a capability statement, required certifications, and SDVOSB verification.
Commercial and Industrial Machinery and Equipment (except Automotive and Electronic) Repair and Maintenance

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541380
New
Federal
Sterile Compounding Services
Solicitation # 36C25727Q0032
The South Texas Veterans Health Care System is seeking a contractor to provide testing and certification services for sterile compounding facilities at the Audie L. Murphy Memorial VA Hospital Pharmacy Service. This firm-fixed-price contract is set aside for Service-Disabled Veteran-Owned Small Businesses (SDVOSB) under NAICS code 541380. The scope of work includes the certification of hazardous drug compounding sterile compounding areas, storage rooms, biosafety cabinets, and laminar flow compounding buffers, as well as monthly viable sampling and personnel competency assessments for hand hygiene, garbing, and hazardous drug manipulation. The contractor must provide all necessary labor, equipment, and documentation, ensuring all work adheres to USP 797, USP 800, IEST RP-CC002, and NSF/ANSI 49 standards. The contract structure consists of a 12-month base period beginning January 11, 2027, with four subsequent 12-month option years. Technical personnel must hold specific credentials, including CETA CNBT Registered Cleanroom Certification Professional and NSF/ANSI 49 Biosafety Biocid Filter Certifier certifications. Award decisions will be based on a comparative evaluation of technical capability, past performance, and price. Proposals must be submitted in three separate volumes: a technical approach limited to 15 pages, a past performance volume featuring at least three similar contracts of at least 100k in value, and a firm-fixed price schedule. All testing must be performed using NIST traceable equipment, and the contractor must provide evidence that no employees are on the OIG excluded parties list.
Testing Laboratories and Services

POSTED

1 day ago

DEADLINE

in 14 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS